Centene Corporation (0HVB.L)
USD 62.91
(0.08%)
USD 62.91
(0.08%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 506 Million USD | -94.54% |
| 2022 | 9.25 Billion USD | -2.98% |
| 2021 | 9.54 Billion USD | 26.95% |
| 2020 | 7.51 Billion USD | 215.05% |
| 2019 | 2.38 Billion USD | 77.53% |
| 2018 | 1.34 Billion USD | 114.35% |
| 2017 | 627 Million USD | -13.52% |
| 2016 | 725 Million USD | 234.51% |
| 2015 | -539 Million USD | 26.77% |
| 2014 | -736 Million USD | -138.96% |
| 2013 | -308 Million USD | 58.71% |
| 2012 | -745.93 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -91 Million USD | -121.93% |
| 2024 Q1 | 415 Million USD | -75.36% |
| 2024 Q3 | 3.02 Billion USD | 3427.47% |
| 2023 Q3 | 917 Million USD | -78.08% |
| 2023 Q2 | 4.18 Billion USD | -27.73% |
| 2023 Q1 | 5.78 Billion USD | -37.49% |
| 2023 FY | 1.68 Billion USD | -81.81% |
| 2023 Q4 | 1.68 Billion USD | 83.64% |
| 2022 Q3 | 6.57 Billion USD | -25.2% |
| 2022 Q2 | 8.79 Billion USD | -23.08% |
| 2022 Q1 | 11.43 Billion USD | 19.79% |
| 2022 FY | 9.25 Billion USD | -2.98% |
| 2022 Q4 | 9.25 Billion USD | 40.78% |
| 2021 Q1 | 8.7 Billion USD | 51.88% |
| 2021 Q2 | 7.29 Billion USD | -16.16% |
| 2021 FY | 9.54 Billion USD | 26.95% |
| 2021 Q3 | 9.27 Billion USD | 27.16% |
| 2021 Q4 | 9.54 Billion USD | 2.88% |
| 2020 Q1 | 7.72 Billion USD | 450.07% |
| 2020 FY | 7.51 Billion USD | 215.05% |
| 2020 Q3 | 4.4 Billion USD | 16.73% |
| 2020 Q2 | 3.77 Billion USD | -51.17% |
| 2020 Q4 | 5.72 Billion USD | 30.15% |
| 2019 Q2 | 55 Million USD | -87.56% |
| 2019 Q1 | 442 Million USD | -67.36% |
| 2019 FY | 2.38 Billion USD | 77.53% |
| 2019 Q4 | 1.4 Billion USD | 113.05% |
| 2019 Q3 | 659 Million USD | 1098.18% |
| 2018 Q1 | -376 Million USD | -155.54% |
| 2018 FY | 1.34 Billion USD | 114.35% |
| 2018 Q3 | -321 Million USD | -8.45% |
| 2018 Q4 | 1.35 Billion USD | 521.81% |
| 2018 Q2 | -296 Million USD | 21.28% |
| 2017 Q3 | 489 Million USD | 42.15% |
| 2017 Q4 | 677 Million USD | 38.45% |
| 2017 Q1 | -124 Million USD | -115.84% |
| 2017 Q2 | 344 Million USD | 377.42% |
| 2017 FY | 627 Million USD | -13.52% |
| 2016 Q1 | 850 Million USD | 256.83% |
| 2016 FY | 725 Million USD | 234.51% |
| 2016 Q4 | 783 Million USD | 2.76% |
| 2016 Q3 | 762 Million USD | -18.85% |
| 2016 Q2 | 939 Million USD | 10.47% |
| 2015 Q3 | -389 Million USD | 52.73% |
| 2015 Q2 | -823 Million USD | -52.13% |
| 2015 Q1 | -541 Million USD | 26.49% |
| 2015 FY | -539 Million USD | 26.77% |
| 2015 Q4 | -542 Million USD | -39.33% |
| 2014 Q3 | -572.62 Million USD | -81.85% |
| 2014 Q2 | -314.89 Million USD | 22.64% |
| 2014 Q1 | -407.03 Million USD | -32.15% |
| 2014 FY | -736 Million USD | -138.96% |
| 2014 Q4 | -736 Million USD | -28.53% |
| 2013 Q4 | -308 Million USD | -37.9% |
| 2013 Q2 | -140.23 Million USD | 29.19% |
| 2013 Q3 | -223.35 Million USD | -59.26% |
| 2013 Q1 | -198.05 Million USD | 73.45% |
| 2013 FY | -308 Million USD | 58.71% |
| 2012 FY | -745.93 Million USD | 0.0% |
| 2012 Q4 | -745.93 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Phreesia, Inc. | -75.53 Million USD | 769.87% |
| Accuray Incorporated | 103.58 Million USD | -388.483% |
| Align Technology, Inc. | -840.47 Million USD | 160.204% |
| Elevance Health Inc. | 18.59 Billion USD | 97.279% |
| AxoGen, Inc. | 32.26 Million USD | -1468.214% |
| Boston Scientific Corporation | 8.23 Billion USD | 93.853% |
| CVS Health Corporation | 71.18 Billion USD | 99.289% |
| Cardinal Health, Inc. | 476 Million USD | -6.303% |
| DaVita Inc. | 10.65 Billion USD | 95.25% |
| HCA Healthcare, Inc. | 40.92 Billion USD | 98.764% |
| Hologic, Inc. | 374.4 Million USD | -35.15% |
| Humana Inc. | 5.51 Billion USD | 90.832% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | -2.44% |
| Laboratory Corporation of America Holdings | 5.41 Billion USD | 90.66% |
| Masimo Corporation | 804 Million USD | 37.065% |
| McKesson Corporation | 889 Million USD | 43.082% |
| Patterson Companies, Inc. | 648.47 Million USD | 21.971% |
| Quest Diagnostics Incorporated | 4.68 Billion USD | 89.195% |
| ResMed Inc. | 635.57 Million USD | 20.387% |
| Henry Schein, Inc. | 2.57 Billion USD | 80.311% |
| Teladoc Health, Inc. | 468.6 Million USD | -7.981% |
| Universal Health Services, Inc. | 5.24 Billion USD | 90.357% |
| Veeva Systems Inc. | -647.71 Million USD | 178.121% |
| Baxter International Inc. | 11.16 Billion USD | 95.468% |
| Becton, Dickinson and Company | 14.46 Billion USD | 96.501% |
| Intuitive Surgical, Inc. | -2.66 Billion USD | 119.02% |
| Danaher Corporation | 13.49 Billion USD | 96.25% |
| Stryker Corporation | 10.02 Billion USD | 94.952% |
| Medtronic plc | 23.67 Billion USD | 97.863% |